Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend its previously announced Early Warrant Exercise Incentive Program (the “Incentive Program”) from April 28, 2022 to May 31, 2022. The Incentive Program is a period during which holders of the Company’s eligible common share purchase warrants (“Eligible Warrants”) may take advantage of a temporary reduction in the exercise price of the Eligible Warrants to a price of C$0.26 “Incentive Exercise Price“) and is more fully detailed in the Company’s March 11, 2022 news release. The extension of the Incentive Program is subject to final approval of the TSX.

2022-04-13 PR